Northwind Pharmaceuticals

New drugs approved for 2014-A Recap of What We’ve Seen This Year

New-drugs-approved-for-2014-A-Recap-of-What-We’ve-Seen-This-YearAs we look back on 2014, it’s been a big year when it comes to newly approved medications. The FDA has been busy, with a long list of both generic and brand name pharmaceuticals getting their stamp of approval. Let’s talk highlights.

  • Cardiology and Vascular Diseases – Zontivity:  For the reduction of thrombotic cardiovascular events.
  • Family Medicine – Arnuity Ellipta: For the treatment of asthma.
  • Gastroenterology – Cyramza: For the treatment of gastric cancer.
  • Genetic Disease – Alprolix:  For the treatment of hemophilia B.
  • Immunology – Triumeq: For the treatment of HIV-1.
  • Musculoskeletal – Vimizim: For the treatment of Mucopolysaccharidosis type IVA.
  • Nephrology – Harvoni: For the treatment of hepatitis C.
  • Neurology – Belsomra: For the treatment of insomnia.
  • Nutrition and Weight Loss – Contrave: For chronic weight management.

To see a full list of all 2014 FDA approved medications click here.

Available pharmaceuticals change from year to year, with more being added all the time. When you partner with Northwind Pharmaceuticals, you have access to top industry information on the best medications to prescribe to your patients. When drugs become available, we’ll track them down and provide you with a competitive price supported by our responsive customer service. Contact us today to see how our solutions can lead to greater success in 2015.

Schedule a free claims analysis now.

Let’s Talk now


Betsy Bigler | Mar 7th, 2024
INDIANAPOLIS, March 7, 2024 – Northwind has announced the addition of Tony Purkey as Senior Vice President, Client Strategies. “Demand from our self-funded employer and union clients is driving rapid growth,” said Phillip Berry, CEO. “Tony Purkey joins Northwind at a time when we need high-integrity leaders with expert knowledge in employer-sponsored health and the … more »

continue reading

Voices Lost in the Noise

Phillip Berry | Jan 31st, 2024
In the health benefits world, the mad scramble toward January renewals/starts has subsided and attention has turned to the annual cycle of review necessary to gauge progress. How did we do? The plan review process generally centers on analytics to gauge progress or regress and to identify “areas of opportunity.” Good. The right data with … more »

continue reading